Coldstream Laboratories for Parental Dosage Forms NCI Contract - - BioPharm International

ADVERTISEMENT

Coldstream Laboratories for Parental Dosage Forms NCI Contract



Coldstream Laboratories, a provider of sterile drug-product development and manufacturing services, has been awarded a five-year contract with the National Cancer Institute (NCI), with the objective of developing and producing pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products.

Coldstream Laboratories, based in Lexington, Kentucky, is a privately held CMO. It was formed in 2007 as a spin off from the University of Kentucky's Center for Pharmaceutical Sciences and Technology.

Source: Coldstream Laboratories

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines

Click here